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Abstract 
In metastatic castration-resistant prostate cancer (mCRPC) clinical trials, the assessment 
of treatment efficacy essentially relies on the time-to-death and the kinetics of prostate-
specific antigen (PSA). Joint modelling has been increasingly used to characterize the 
relationship between a time-to-event and a biomarker kinetics but numerical difficulties 
often limit this approach to linear models. Here we evaluated by simulation the capability 
of a new feature of the Stochastic Approximation Expectation-Maximization algorithm in 
Monolix to estimate the parameters of a joint model where PSA kinetics was defined by a 
mechanistic nonlinear mixed-effect model. The design of the study and the parameter 
values were inspired from one arm of a clinical trial. Increasingly high levels of association 
between PSA and survival were considered and results were compared with those found 
using two simplified alternatives to joint model, a two-stage and a joint sequential model. 
We found that joint model allowed for a precise estimation of all longitudinal and survival 
parameters. In particular the effect of PSA kinetics on survival could be precisely 
estimated, regardless of the strength of the association. In contrast, both simplified 
approaches led to bias on longitudinal parameters and two-stage model systematically 
underestimated the effect of PSA kinetics on survival.  
In summary we showed that joint model can be used to characterize the relationship 
between a nonlinear kinetics and survival. This opens the way for the use of more complex 
and physiological models to improve treatment evaluation and prediction in oncology. 
 
Keywords: metastatic prostate cancer, PSA, NLMEM, joint model, SAEM 
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Introduction 
Prostate cancer is the second most frequently diagnosed cancer in men and is responsible 
for about 300 000 deaths worldwide every year [1]. Although treatment can be effective, 
a number of factors, such as resistance or delayed treatment (4% of cancer have 
metastasized at diagnosis [2]) considerably worsen the treatment outcome. In the case of 
metastatic castration-resistant prostate cancer (mCRPC), the evaluation of chemotherapy 
efficacy primarily relies on the overall survival [3] and is complemented by the analysis of 
the Prostate-Specific Antigen (PSA). Although countless studies have explored the 
relationship between different PSA kinetic parameters (such as doubling time or time to 
nadir) and survival, the choice of a clearly-defined parameter remains controversial.  
The lack of consensus on how to use PSA kinetics is exacerbated by the difficulty to 
properly handle PSA kinetics and the time-to-event (time-to-death or dropout) in statistical 
models. Several methods have been proposed in the literature. The simplest one is to 
plug the individual PSA kinetic parameters into a survival model [4]. However the fact that 
these parameters are often not directly observed from the data makes this approach error 
prone. A second approach is to use a model to describe the entire PSA kinetics using 
mixed-effect models to precisely account for between-subjects variability, and then to plug 
individual model predictions as covariates in a survival model [5,6]. However this method, 
called in the following “two-stage” approach, is prone to bias because it does not take into 
account the relationship between the marker’s kinetic and the time-to-event and the 
uncertainty in the individual model predictions [7]. In order to eliminate the bias found in 
the two-stage approach, one can use models which simultaneously, or “jointly”, handle 
longitudinal and time-to-event data [7–13]. For the latter, one can either aim to estimate 
all parameters simultaneously (“joint” model) or in a sequential manner (“joint sequential” 
model), as it has been suggested in the pharmacometric field [14].    
The main challenge in using joint model is the numerical complexity involved by the 
calculation and the maximization of the likelihood. This difficulty can be circumvented by 
using a linear model for the PSA kinetics as implemented in the large majority of published 
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models [7,15] or softwares [16]. However this precludes the use of physiologically more 
accurate models for PSA kinetics which are in essence nonlinear.  
In the last years, pharmacometric softwares have addressed the need for joint model 
when the longitudinal model is defined by a nonlinear mixed-effect model (NLMEM). This 
approach was firstly implemented in NONMEM using a Laplacian approximation of the 
likelihood and was essentially used to account for informative dropouts [17,18]. Recently 
the Stochastic Approximation Expectation-Maximization (SAEM) algorithm, a method 
relying on an “exact” calculation of the likelihood, was extended to include time-to-event 
data [19,20] in Monolix and NONMEM. 
Here we evaluated the benefit of joint models using the SAEM algorithm for characterizing 
the relationship between survival and a biomarker having a non-linear kinetics. We 
compared by simulation the precision and the type 1 error of longitudinal and survival 
parameters obtained using a joint, a joint sequential and a two-stage model in the context 
of a clinical study in mCRPC according to the strength of the association between PSA 
kinetics and survival. 
 
Models and notations 
A Mechanistic model for PSA kinetics 
In absence of treatment we assume that prostatic cells, C (mL-1), proliferate with rate r 
(day-1) and are eliminated with rate d (day-1). PSA (ng.mL-1) is secreted with a production 
rate p (ng.day-1) and cleared from the blood with rate δ (day-1). We suppose that a 
chemotherapy for mCRPC acts by blocking cell proliferation with time-varying 
effectiveness, e(t), and hence the proliferation rate under treatment is given by  =
1 − 	
 with 0 ≤ 	
 ≤ 1 (Figure 1): 
  = 1 − 	

	
 − 	
	 = 	
 − 	
																			 (1) 
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Treatment is initiated at t=0, PSA(0)=PSA0 and C(0)=C0 are PSA value and the number 
of prostatic cells at treatment initiation respectively. Here, treatment is assumed to be 
constantly effective until a certain time, Tesc, after what tumor escapes and treatment has 
no longer an effect: 
	
 = 			 		 ≤ !"#$0			 		 > !"#$    (2) 
Further, we made the assumption of quasi steady-state at treatment initiation and thus 
& = '×)*  . With this piecewise constant treatment effect (2), the model (1) has an 
analytical solution given by: 
	, ,
 =
 ')-./0
/1' 	-./0
/
 + 3& − ')-./0
/1'4 /'																																					 		 ≤ !"#$')-/1' 	-/
/-05678 + 3!"#$
 − ')"9:;<
;=
>678-/1' 4 /'/5678
										 		 > !"#$							(3) 
Because only 4 parameters can be identified from Eq. 3 ,we fixed d to 0.046 day-1 , 
corresponding to a half-life of tumor cells of 15 days, consistent with an apoptotic index of 
5% in metastatic prostate cancer [21]. Moreover we fixed δ to 0.23 day-1, corresponding 
to a PSA half-life in blood of about 3 days [22]. Thus PSA kinetics was defined by the 
vector parameter ψ={r, PSA0, ε and Tesc}. 
Statistical model for PSA measurements 
Let yij denote the jth longitudinal measurement of log(PSA+1) for the individual i at time tij, 
where i=1, …, N, j=1, …, ni, N is the number of subjects and ni the number of 
measurements in subject i. The nonlinear mixed-effect model (NLMEM) for PSA is defined 
as follows: 
@AB = log	AB, ,A + 1 + FAB     (4), 
where PSA is given by the formula (3), ψi is the vector of the individual parameters and eij 
the residual error which follows a standard normal distribution with mean 0 and variance 
1. The vector of the individual parameters ψi is decomposed as fixed effects µ={r, PSA0, 
ε, Tesc} representing median effects of the population and random effects ηi specific for 
each individual. It is assumed that ηi∼N(0, Ω) with Ω the variance-covariance matrix. In 
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this work, Ω is supposed to be diagonal. Each diagonal element ωq2 represents the 
variance of the qth component of the random effect vector ηi. We assumed log-normal 
distribution for r, PSA0 and Tesc: 
logψH,A = logIH + ηH,A 
and logit-normal distribution for ε: 
KLM	A
 = KLM	μ0
 + η0,A with KLM	O
 = log	P Q./QR for 0<x<1. 
The population parameters vector of PSA noted θl is composed of {µ, Ω, σ}. 
Statistical model for survival  
Let Xi denote the time to event and Ci the censoring time for the ith subject. Survival data 
(Ti, δi) are observed in all individuals, where Ti=min(Xi, Ci) and δT = 1, if	XT ≤CT, 0	otherwise. For the event process, we used a hazard function of the form: 
ℎA	|	, ,A
 = ℎ&	
 expc	, ,A
     (5) 
where the baseline hazard function, h0, is a Weibull hazard function ℎ&	
 = de PeRd/.. The 
parameter β measures the strength of the association between the PSA kinetics and the 
risk of death. If β=0, the survival process is independent on the PSA evolution and survival 
data can be fitted by a Weibull model without adjusting for PSA. If β≠0, the survival 
process depends on the PSA kinetics. The survival parameters to estimate are θs={λ, k, 
β}. 
Joint model 
Joint models assume conditional independence: given the random effects ηi, longitudinal 
measurements and survival events are independent. All parameters, f = {fh, f#}  are 
simultaneously estimated. Thus the joint log-likelihood for subject i can be written as follow 
[23]: 
KAf
 = log	j @A|kA; f
mℎA!A|kA; f
'nA!A|kA; f
okA; f
kA     (6) 
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where A	|kA ; f
 = exp P	−j ℎ&p|kA ; f
exp	cp, ,A
& 
pR  is the survival function 
conditionally on the random effects, @A|kA; f
 the density of the longitudinal observations 
conditionally on the random effects and kA; f
 the density of the random effects. 
Two-stage model 
In order to simplify the heavy calculations involved by Equation (6) one may also use a 
two-stage approach. In the first step PSA kinetics parameters (θl) are estimated assuming 
complete independence of PSA kinetic and survival and the Empirical Bayes Estimates 
(EBEs), defined as the mode of the conditional distribution ,A|@A , fqh
, are used to provide 
individual parameters, noted ,qA . In the second step, the survival parameters (θs) are 
estimated maximizing the usual log-likelihood Kf#
 =
∑ KLM sℎA!At	, ,qA; f#
'nA!At	, ,qA; f#uvAw. . 
This method is analogous to the sequential method called “Individual Pharmacokinetic 
Parameters” (IPP) used in pharmacometric field  to handle 
PharmacoKinetic/PharmacoDynamic (PKPD) data [14]. 
Joint sequential model 
In order to reduce the number of parameters to estimate in Equation (6), an alternative 
consists in first estimating population PSA kinetic parameters, as done in the two-stage 
model, and then estimating parameters related to survival (θs) fixing the all population 
PSA parameters (θl) in Equation (6) to the values obtained at the previous stage. This 
method, inspired  from the “Population PK parameter and individual PK data” for the 
combined analysis of PKPD data, has been shown to limit the bias compared to two-stage 
approach [14].  
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Simulation study 
Design 
Simulation setting was inspired by one arm of a phase III study of clinical development of 
chemotherapy for metastatic prostate cancer [3]. M=100 datasets with N=500 patients 
were simulated with PSA measurements every 3 weeks for 2 years (i.e., the last possible 
measurement time was at t=735 days), leading to a maximum of 36 observations per 
patient (Table I). Follow-up was censored at t=735 and no other mechanism than death 
was considered for dropout. For the simulation of the time to death, k was fixed to 1.5, 
and 3 values for β were considered: 0, 0.005 and 0.02, corresponding to ‘no link’, ‘low link’ 
and ‘high link’ between PSA kinetics and survival, respectively. In order to maintain a 
comparable amount of PSA measurements across scenarios, λ was determined in each 
scenario such that the probability of survival at the end of the follow-up (i.e., 735 days) 
was equal to 25% with the median PSA kinetic parameters (Table I), leading to λ=580, 
765 and 2150 in scenarios ‘No link’, ‘Low link’ and ‘High link’, respectively (Table II). Lastly, 
we evaluated the effects of having both a large baseline risk and a strong effect of PSA 
kinetics by setting β=0.02 and λ=580 in the scenario called ‘Short survival’. Figure 2 shows 
the survival functions for these 4 scenarios for the “median patient”, i.e., a virtual patient 
having PSA kinetic parameters equal to the median values in the population.  
In order to take into account the effect of withdrawals from PSA follow-up, we also 
explored additional scenarios where PSA and/or vital status were censored in case of 
PSA progression defined as an increase of 25% above the nadir and of at least 2 ng/ml 
compared to nadir (see supplementary file 1).  
All simulations were carried out with the R software version 3.0.1 [24]. 
Parameter estimation  
The estimation of two-stage, joint sequential and joint models was performed for each 
dataset and each scenario using the Stochastic Approximation Expectation-Maximization 
(SAEM) algorithm in the software Monolix version 4.2.2.  
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The initial values of the parameters were those used for the scenario ‘No link’. Minus twice 
log-likelihood (-2LL) was calculated by Importance Sampling, fixing the Monte-Carlo sizes 
to achieve a sufficient level of precision for Likelihood Ratio Test (LRT) to 100 000 Monte-
Carlo sizes for the scenario ‘No link’, 20 000 for the other scenarios in joint model and 
2 000 in two-stage model. 
SAEM was run using 1 chain and we verified that using 3 chains, as suggested in a related 
context [19], gave similar results. CPU (Central Processing Unit) times for parameters 
estimations and -2LL estimations were recorded on a i7 64bits 3.33GHz. 
Evaluation criteria 
We used Relative Estimation Errors defined by: xyyfqz = 	 {|};{∗{∗ × 100,	where f∗and fqz 
are the true and estimated parameters, respectively, for dataset m, m=1…M. Boxplots of 
the REEs with the 10% and 90% percentiles were plotted. When β=0 (scenario ‘No link’), 
the boxplot of the absolute estimation error, cd, with the 10% and 90% percentiles were 
plotted .  
The type 1 error and power were calculated as the proportion among the M datasets for 
which LRT (called in the following “uncorrected LRT”) led to reject the null hypothesis H0: 
β=0. The type 1 error was evaluated in the scenario ‘No link’ and the power was calculated 
for the 3 other scenarios. The significance level of the tests α for the observed type 1 error 
was fixed to 0.05, leading to a 95% prediction interval for 100 replicates equal to [0.7%-
9.3%]. 
In some cases the estimation of -2LL, which relies on a stochastic approximation, was 
associated with a non-negligible standard error. Because this can lead to an inflation of 
the type 1 error, we also evaluated a “corrected LRT”. In this test H0 was rejected if 
−2&
 + 2.
 was larger than . + p/&
 + p/.
	; 	∞
 where -se-
2LL(H0) and se-2LL(H1) are the estimated standard error of -2LL under H0 and H1, 
respectively, whereas . and  are the chi-squared value with 1 degree of freedom and 
the αth quantile of the standard normal distribution, respectively. 
se/H&
 + se/H.
 is the uncertainty for the sum of the two estimated -2LL. We 
used a corrected LRT if p/&
 + p/.
	 was non negligible compared to 
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., i.e., for a significance level of 5%, p/&
 or p/.
 non negligible compared 
to 2. 
Results 
Simulated data 
Figure 3 shows the spaghetti-plots along with the Kaplan-Meier curves of one typical 
dataset for each of the 4 scenarios. Because the scenario ‘No link’ assumes that death 
does not depend on PSA kinetics, PSA rebound after loss of treatment efficacy (at time 
Tesc) was more frequently observed than in the 3 other scenarios. As expected (see 
methods), the numbers of measurements in the first 3 scenarios were largely similar 
(Table III). In the last scenario where both the baseline hazard function and the effect of 
PSA kinetics were large, early events frequently occurred and the total amount of PSA 
data was much smaller. 
Estimation performance 
No bias was observed in the scenario ‘No link’ regardless of the approach. In the two-
stage approach, increasing effect of PSA on survival led to higher levels of bias (Figures 
4 and 5). In particular there was a systematical underestimation of the PSA effect on 
survival with median (Q1;Q3) REE  for β equal to -8.4% (-12.6 ; -4.1), -14.8% (-18.9 ; -
10.2) and -9.1% (-16.7 ; -5.7) in scenarios ‘Low link’, ‘High link’ and ‘Short survival’, 
respectively. The bias was corrected by using joint sequential models or joint models, with 
median (Q1;Q3) REE for β of 0.005% (-3.6 ; 5.3), -0.6% (-3.3 ; 2.9) and 0.03% (-4.8 ; 5.7) 
in scenarios ‘Low link’, ‘High link’ and ‘Short survival’, respectively for this latter method. 
Although the three approaches led to low REEs for the almost all parameters of PSA 
kinetics (Figure 4), a bias was observed for the proliferation rate of tumor cells, r, with 
median (Q1;Q3) REE equal to -0.4% (-0.7 ; -0.05), -0.8% (-1.0 ; -0.5) and -1.2% (-1.8 ; -
0.7) in scenarios ‘Low link’, ‘High link’ and ‘Short survival’, respectively, when using the 
two-stage or joint sequential approach. Here as well, the bias was largely reduced when 
using a joint model, with median (Q1;Q3) REE for r equal to 0.01% (-0.4 ; 0.3), -0.004% 
(-0.3 ; 0.2) and -0.08% (-0.6 ; 0.5), in scenarios ‘Low link’, ‘High link’ and ‘Short survival’, 
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respectively. Of note large REE were found for the parameters λ and k (|REE|>30%) in 
the scenario ‘High link’ when using joint and joint sequential models, due to the presence 
of a local extremum of the likelihood function.  
Lastly we also considered additional scenarios where PSA data and/or vital status were 
censored in case of PSA increase (see supplementary file 1). Although the precision of 
the parameter estimates was deterioriated due to the reduction in the amount of data 
available no substantial bias in the PSA kinetic parameters was found. However bias was 
found in survival related parameters, in particular when both PSA and vital status were 
censored after disease progression and this bias systematically led to an overestimation 
of the hazard function. 
Test performance 
The uncorrected LRT led to a type 1 error of 21%, 9% and 12% for the joint model, the 
joint sequential model and the two-stage model, respectively, i.e., outside the 95% 
prediction interval ([0.7%-9.3%] for 100 replicates). The use of a corrected LRT (see 
methods) led to a smaller type 1 error of 4%, 3% and 12% for the joint model, the joint 
sequential model and the two-stage model, respectively. The reason why the type 1 error 
for the two stage model with or without correction were similar is due to the fact that the 
standard error of -2LL were negligible with this model (<10-4). For the scenarios with β≠0, 
the power was 100% with all three models, regardless of the correction. 
Computation time 
Mean CPU times for the simultaneous estimation of the 12 parameters using joint model 
were about 5 times larger than the total CPU times using two-stage model (70 vs 14 
minutes) and about 1.2 times larger than the total CPU times using joint sequential model 
(70 vs 59 minutes), ignoring time for specific data manipulation required for setting the 
two-stage and joint sequential approaches. Mean CPU times for the -2LL estimation using 
joint model (respectively joint sequential model) and 100,000 chains was about 3.1 
(respectively 3.6) times larger than when using the joint approach and 20,000 chains (264 
vs 86 minutes (respectively 207 vs 57 minutes)) but led to a mean se
-2LL(H1) of 1.96  vs 
5.14 (respectively 2.40 vs 5.90). 
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Discussion 
Numerical complexities have long limited the use of joint models to longitudinal processes 
defined by linear mixed-effect models [7,10,15]. Here we evaluated by simulation, in the 
context of PSA and survival in metastatic prostate cancer, the capability of a new feature 
of the Stochastic Approximation Expectation-Maximization algorithm in Monolix to 
estimate the parameters of a joint model where the longitudinal process was defined by a 
nonlinear model. And we compared the results to two simplified approaches, two-stage 
and joint sequential models. 
We found that joint model provided unbiased parameters of both longitudinal and survival 
processes. In contrast, the use of a two-stage model [5,25] led to large biases when PSA 
kinetics and survival were linked. In particular, the impact of the biomarker kinetics on the 
survival, as measured by the link parameter β, was systematically underestimated, 
consistent with results found in linear mixed-effect model [8,9]. Beside survival 
parameters, a bias on the tumor proliferation rate, r, which is the driving force for the 
increase in PSA, was also observed in scenarios with β≠0. The fact that no such bias 
occurred when using joint model shows that the simultaneous estimation of the hazard 
function also improved the estimation of the longitudinal parameters. Moreover, a two-
stage approach led to an inflation of type 1 error (i.e., conclude to an effect of PSA on 
survival while there is none) which could be explained by the shrinkage of the EBEs in 
patients with short survival [26]. By construction the joint sequential model led to the same 
biases on PSA longitudinal parameters than the two-stage model, but the estimation of 
survival parameters was close to that obtained with the joint model. This, therefore, 
suggests that joint sequential model could be a relevant approach when joint model 
cannot be performed.  
In spite of the increasing numerical capability, the likelihood of joint models remains 
particularly complex to calculate. Here we reported that the likelihood was estimated with 
a relatively large uncertainty. Increasing the Monte-Carlo sizes led to smaller standard 
errors of the likelihood but considerably increased the computation time. The impact of 
this error on type 1 error was in part accounted by using a corrected likelihood ratio test 
(LRT). However more studies will be needed to precisely determine when this correction 
13 
 
is necessary and whether it can be improved. Here for instance the corrected rejection 
region did not take into account the covariance between the likelihood calculated under 
the null and alternative hypotheses. Although the Wald test may be an alternative, we 
found here that standard errors of the estimates tended to be smaller than the Root Mean-
Squared Errors (RMSE), indicating a potential underestimation of the standard errors. 
Furthermore, and in spite of the stochastic algorithm, the estimation of parameters related 
to survival was complicated in some cases by the existence of local extremum of the 
likelihood function. This stresses the need, in practice, to perform several runs of likelihood 
maximization using different initial values.   
The main advantage of nonlinear models is the possibility to develop physiological models 
based on nonlinear differential equations, which naturally integrate the correlations 
between the different biomarkers. In this study, we used a rather simple model where the 
treatment effectiveness was piecewise constant, which allowed us to derive a 
biexponential analytical solution for the PSA kinetics. However this model may clearly be 
over-simplistic and more complex models will be needed that rely on several markers, 
such as tumor size or drug pharmacokinetics. The facilitated use of these models via joint 
models holds the promise that the determinants of survival may be much better 
characterized [20].  
Regarding the survival model, we restricted here to a rather simple fully parametric model, 
where the baseline hazard function was a Weibull model [27] and the hazard function was 
related to the current PSA values. In practice complex survival models could be evaluated 
and standard tools for model selection (e.g., AIC or BIC) could be used to evaluate the 
effect of various transformations of the biomarker, such as the derivative or the cumulative 
value of PSA. Lastly with a fully parametric model the prediction and the simulation of the 
individual hazard function can easily be performed, making possible to guide treatment 
adaptation in a dynamic manner [28].  
Conclusion 
SAEM algorithm implemented in Monolix was shown to provide precise estimates for joint 
models where the longitudinal model was defined by a non-linear mixed-effect model. This 
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opens the way for a more systematic use of joint models and a better understanding of 
the relationship between biomarker kinetics and survival, especially in the field of 
metastatic cancer where survival and non-linear biomarker kinetics are intrinsically 
related. 
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Table I: Values of the population PSA parameters used for the simulations in all 
scenarios 
  Fixed 
effects 
Transformation Inter-individual  
standard deviation (ω) 
r (day-1) 0.05 log-normal 0.1 
PSA0 (ng.mL-1) 80 log-normal 0.6 
ε 0.3 logit-normal 1.5 
Tesc
 
(day) 140 log-normal 0.6 
σ 0.36 - - 
 
 
Table II: Values of the population survival parameters used for the simulations of the 
4 scenarios 
 Scenario No 
link Scenario Low link 
Scenario High 
link 
Scenario Short 
survival 
β 0 0.005 0.02 0.02 
λ (day) 580 765 2150 580 
k 1.5 1.5 1.5 1.5 
 
 
Table III: Number of PSA measurements per patient and median survival in the total 
number of simulated (50000) patients for the 4 simulated scenarios 
Number of 
PSA 
measurements 
Scenario
 
No 
link 
Scenario Low 
link 
Scenario High 
link 
Scenario Short 
survival 
1-5 7% 7% 8% 29% 
6-10 12% 13% 10% 20% 
11-20 26% 31% 22% 26% 
21-35 30% 29% 21% 17% 
36 24% 21% 39% 8% 
Median 
survival (day) 457 414 552 217 
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Figure 1: Schema of the secretion of PSA by prostate and cancer cells. PSA is 
expressed in ng.mL-1 and C in mL-1. r is the rate of prostatic cells proliferation in 
absence of treatment (day-1), d the rate of prostatic cells elimination (day-1), p the rate 
of PSA secretion by C (ng.day-1), δ the rate of PSA elimination (day-1) and e(t) the time-
dependent treatment effect. 
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Figure 2: Typical evolution of PSA(t) (solid black) and survival functions in the typical 
patient (who have the fixed effects of the Table I as PSA parameter) for the scenarios 
‘No link’ (β=0, λ=580) (solid orange), ‘Low link’ (β=0.005, λ=765) (dashed green), ‘High 
link’ (β=0.02, λ=2150) (dotted blue) and ‘Short survival’ (β=0.02, λ=580) (dotdash 
purple)  
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Figure 3: Spaghetti-plots (black lines) and estimated Kaplan-Meier curves (colored 
lines) for one typical dataset (N=500) for each of the four scenarios 
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Figure 4: Boxplots of the relative estimation errors for parameters related to PSA for 
two-stage model (blue), joint sequential model (purple) and joint model (red), for the 4 
scenarios. Top left: scenario No link (β=0, λ=580), top right: scenario Low link 
(β=0.005, λ=765), bottom left: scenario High link (β=0.02, λ=2150) and bottom right: 
scenario Short survival (β=0.02, λ=580). 
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Figure 5: Boxplots of the relative estimation errors for parameters related to survival 
(in % except for β of the scenario No link for which estimated values are represented) 
for two-stage model (blue), joint sequential model (purple) and joint model (red), for 
the 4 scenarios. Top left: scenario No link (β=0, λ=580), top right: scenario Low link 
(β=0.005, λ=765), bottom left: scenario High link (β=0.02, λ=2150) and bottom right: 
scenario Short survival (β=0.02, λ=580). 
 
 
 
 
 
23 
 
Supplementary file 1: Impact of withdrawal from PSA follow-up on 
joint estimation 
 
 
 
 
 
It is frequent in clinical trial protocols that treatment is stopped when a disease progression 
(increase in PSA or tumor size, adverse events) is observed. When treatment is stopped, the 
patient may drop out of the study. Although the vital status may continue to be collected, the 
PSA measurements are no longer recorded in the study. 
 
Simulation framework 
 
For the sake of simplicity we consider here that a disease progression was only due to a PSA 
progression defined as an increase of 25% above the nadir and of at least 2 ng/ml compared 
to nadir. PSA data were removed accordingly in all datasets of the scenarios ‘No link’, ‘High 
link’ and ‘Short survival’ (see main analysis), leading to a dramatic decrease in the number of 
PSA measurements (Table S1).  
In order to assess the impact of withdrawal data, two cases were considered: 
 The vital status is known at the end of the study (scenarios ‘Withdrawal’) 
 The vital status is censored at the time of the disease progression (scenarios 
‘Withdrawal + censor’) 
 
Thus, in the first case the number of observed deaths is equal to that observed in the main 
analysis, and in the second case the number of observed deaths is much smaller that observed 
in the main analysis (scenarios ‘No withdrawal’). This results in much larger confidence interval 
for the Kaplan-Meier curves (Figure S1). 
 
Results 
 
The variability of the parameter estimates increases when patients withdrawal from PSA 
follow-up (Figures S2 and S3) which was expected because there is a smaller number of PSA 
measurements. PSA kinetic parameters (Figure S2) were not affected by withdrawal, with or 
without censor of vital status. However all three parameters related to survival were estimated 
with a bias in case of censor of survival (Figure S3): β and k tend to be overestimated while λ 
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tends to be underestimated. These trends led to an overestimation of the hazard function and 
hence an underestimation of the survival function. 
 
Conclusion  
 
Drop out caused by predefined levels of PSA progression does not affect the estimation of the 
parameters associated with PSA kinetics.  
Regarding survival parameters, a bias towards an overestimation of the hazard function may 
occur, in particular when not only PSA but also the vital status is not collected after disease 
progression. 
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Table S1: Number of PSA measurements per dataset and per patient and mean number of events per dataset in the total number of simulated 
datasets 
 
Scenario No link Scenario High link Scenario Short survival 
No 
withdrawal Withdrawal 
Withdrawal 
+ censor 
No 
withdrawal Withdrawal 
Withdrawal 
+ censor 
No 
withdrawal Withdrawal 
Withdrawal 
+ censor 
Number of PSA 
measurements per 
dataset 
11 104 3 062 3 062 12102 3488 3488 6 834 2 804 2 804 
Number of 
PSA 
measurements 
per patient 
1-5 7% 65% 65% 8% 64% 64% 29% 70% 70% 
6-10 12% 22% 22% 10% 21% 21% 20% 19% 19% 
11-20 26% 7% 7% 22% 7% 7% 26% 7% 7% 
21-35 30% 3% 3% 21% 3% 3% 17% 3% 3% 
36 24% 1% 1% 39% 4% 4% 8% 1% 1% 
Mean number of events 
per dataset 379 379 66 305 305 36 462 462 145 
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Figure S1: Spaghetti-plots (black lines) and estimated Kaplan-Meier curves (colored solid lines) 
with their 95% confidence interval (colored dashed lines) for one typical dataset (N=500) for each 
scenario, without withdrawal (red curves), with withdrawal after PSA progression (pink curves) 
and with withdrawal and censor after PSA progression (grey curves). 
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Figure S2: Boxplots of the relative estimation errors for the parameters related to PSA for joint 
model without withdrawal (red), with withdrawal (pink) and with withdrawal and censor (gray) and 
for the 3 scenarios. Top: scenario No link (β=0, λ=580), middle: scenario High link (β=0.02, 
λ=2150) and bottom: scenario Short survival (β=0.02, λ=580). 
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Figure S3: Boxplots of the relative estimation errors for the parameters related to survival (in % 
except for β of the scenario No link for which estimated values are represented) for joint model 
without withdrawal (red), with withdrawal (pink) and with withdrawal and censor (gray) and for the 
3 scenarios. Top: scenario No link (β=0, λ=580), middle: scenario High link (β=0.02, λ=2150) and 
bottom: scenario Short survival (β=0.02, λ=580). 
 
 
 
 
